Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 60

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 60
---
 combined financial information reflects adjustments, which are 35

based upon assumptions, preliminary estimates and accounting reclassifications, to record Enfusion’s identifiable assets acquired and liabilities assumed at fair value and the resulting
goodwill recognized. The purchase price allocation reflected in this Proxy Statement/Prospectus is preliminary, and final allocation of the purchase price will be based upon the actual purchase price and the fair value of the assets and liabilities
of Enfusion as of the date of the completion of the Transactions. Accordingly, the final accounting adjustments as a result of the acquisition may differ materially from the pro forma adjustments reflected in this Proxy Statement/Prospectus. For
more information, see the section titled “Unaudited Pro Forma Condensed Combined Financial Information.”

Completion of the Transactions may trigger change in control provisions in certain agreements to which Enfusion is a party.

The completion of the Transactions
may trigger change in control provisions in certain agreements to which Enfusion is a party. If Enfusion and Clearwater are unable to negotiate waivers of those provisions, the counterparties may exercise their rights and remedies under the
agreements, potentially terminating the agreements or seeking monetary damages. Even if Enfusion and Clearwater are able to negotiate waivers, the counterparties may require a fee for such waivers or seek to renegotiate the agreements on terms less
favorable to Enfusion or Clearwater.

Lawsuits may be filed in the future against Enfusion, its directors, Clearwater, Acquirer, Merger Sub and/or Merger Sub II challenging the Transactions or any one of them, and an adverse ruling in any such lawsuit may prevent completing the Transactions or completing the Transactions within the expected timeframe and/or result in substantial costs to Clearwater and Enfusion.

In connection with the Transactions, litigation may be filed against Enfusion and its board of directors.
Among other remedies, the plaintiffs in these lawsuits may seek damages or to enjoin the Transactions. The outcome of any litigation is uncertain and any such lawsuits could prevent or delay the completion of the Transactions and result in
substantial costs to Clearwater and Enfusion. Any such actions may create uncertainty relating to the Transactions and may be costly and distracting to management. Further, the defense or settlement of any lawsuit or claim that remains unresolved at
the time the Transactions are completed may adversely affect Clearwater’s business, financial condition and results of operations.

It is possible that litigation against Enfusion, its directors, Clearwater, Acquirer, Merger Sub and/or Merger Sub II may be filed in the